Clinical trials: Dendritic Cell
Unspecified Adult Solid Tumor, Protocol Specific
Vaccine Therapy in Treating Patients With Refractory Stage IV Cancer
RATIONALE: Vaccines made from a person's white blood cells mixed with peptides may make the body build an immune response to kill cancer cells.
- Trial name
- NCT00057915
- Testing
- CEA peptide 1-6D
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Duke University
Glioblastoma Multiforme
Phase II Feasibility Study of Dendritic Cell Vaccination for Newly Diagnosed Glioblastoma Multiforme
Adult patients who have surgical resection of newly diagnosed glioblastoma multiforme will be treated with radiotherapy/chemotherapy followed by dendritic cell vaccine.
- Trial name
- NCT00323115
- Testing
- Autologous Dendritic Cell, Temozolomide, Radiotherapy
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Dartmouth-Hitchcock Medical Center
Cancer of Skin, Solid Tumors
Peritumoral Injection of Immature Dendritic Cells to Irradiated Skin Metastases of Solid Tumors
Melanoma is the main cause of death in patients with skin cancer. Once it has metastasized, this cancer has been shown to respond to chemotherapy only in rare cases.
- Trial name
- NCT00278018
- Testing
- Immunotherapy treatment for solid tumors
- Where
- Israel
- Volunteers
- 20 people
- Sponsor
- Hadassah Medical Organization
Metastatic Melanoma
Study of Gene Modified Immune Cells in Patients With Advanced Melanoma
The purpose of this phase 2 study is to find the best way to give this new experimental regimen and determine if it can treat metastatic melanoma in humans.
- Trial name
- F5 (NCT00910650)
- Testing
- F5 TCR transgenic cells and MART-1 peptide pulsed dendritic cells, non-myeloablative conditioning chemotherapy
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Graft Versus Host Disease, Leukemia
Chemotherapy, Radiation Therapy, and Umbilical Cord Blood Transplantation in Treating Patients With Hematologic Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage cancer cells.
- Conditions
- Graft Versus Host Disease, Leukemia, Lymphoma, Myelodysplastic Syndromes
- Trial name
- NCT00003661
- Testing
- anti-thymocyte globulin, busulfan, cyclosporine
- Where
- 17 sites in United States
- Volunteers
- 3 people
- Sponsor
- Roswell Park Cancer Institute
Treat and Prevent Covid-19 Infection
Safety and Immunity of Covid-19 aAPC Vaccine
In December 2019, viral pneumonia (Covid-19) caused by a novel beta-coronavirus (SARS-CoV-2) broke out in Wuhan, China. Some patients rapidly progressed and suffered severe acute respiratory failure and died, making it imperative…
- Trial name
- NCT04299724
- Testing
- Pathogen-specific aAPC
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Shenzhen Geno-Immune Medical Institute
Malignant Melanoma Stage III, Malignant Melanoma Stage IV
IL15 Dendritic Cell Vaccine for Patients With Resected Stage III (A, B or C) or Stage IV Melanoma
The purpose of the study is to gather data on feasibility as well as immune and clinical efficacy of of a dendritic cell vaccine using IL15 in patients with resected stage III or stage IV melanoma
- Trial name
- NCT01189383
- Testing
- IL15-DC Vaccine
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Baylor Research Institute
Blastic Plasmacytoid Dendritic Cell Neoplasm, Myeloproliferative Neoplasm
Study of IMGN632 in Patients With Untreated BPDCN and Relapsed/Refractory BPDCN
This is an open-label, multi-center, Phase 1/2 study to determine the MTD and assess the safety, tolerability, PK, immunogenicity, and anti-leukemia activity of IMGN632 when administered as monotherapy to patients with CD123+…
- Trial name
- NCT03386513
- Testing
- IMGN632
- Where
- 29 sites in United States, France and 4 more
- Volunteers
- 179 people
- Sponsor
- AbbVie
Relapsed Non-Hodgkin's Lymphoma, Hodgkin's Disease
Host Dendritic Cells in Allograft Patients
The purpose of this study is to assess preliminary efficacy and to determine the safety and feasibility of ex vivo generated dendritic cell (HDC) infusion with and without donor lymphocyte infusion (DLI) after allogeneic stem…
- Conditions
- Relapsed Non-Hodgkin's Lymphoma, Hodgkin's Disease, Multiple Myeloma, Chronic Lymphocytic Lymphoma
- Trial name
- NCT00935597
- Testing
- MSSM/BIIR HDC Vax-001 (Host Dendritic Cells)
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Icahn School of Medicine at Mount Sinai
Carcinoma, Renal Cell, Vaccination
Vaccination With Dendritic Cells Pulsed With Autologous Tumor Homogenate in Combination With HD-IL2 and Immunomodulating Radiotherapy in Metastatic RCC
Single center, open-label Proof of Principle phase II trial to assess objective response (ORR). Three daily doses boost radiotherapy (XRT) at 6-12 Gy to at least 1, and up to a maximum of 5, metastatic fields, will be…
- Conditions
- Carcinoma, Renal Cell, Vaccination, Secondary
- Trial name
- RENALVax-2 (NCT03226236)
- Testing
- boost radiotherapy (XRT), Autologous DC vaccine, High-Dose IL-2
- Where
- Italy
- Sponsor
- Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
Renal Failure, End Stage
The ONE Study ATDC Trial
To collect evidence of the safety of administering autologous tolerogenic dendritic cells (ATDC) preparations to living-donor renal transplant recipients in the context of an international European Union funded consortium aimed…
- Trial name
- ONEatDC (NCT02252055)
- Testing
- ATDC_Nantes
- Where
- France
- Volunteers
- 11 people
- Sponsor
- Nantes University Hospital
Solid Tumor, Metastases to Soft Tissue
Intratumoral Injection of Autologous CD1c (BDCA-1)+ myDC, AS01B, and Ipilimumab Plus Systemic Nivolumab
This phase II trial aims at investigating the role and effect of autologous CD1c (BDCA-1)+ myeloid dendritic cells in combination with intratumoral injection of the CTLA-4 blocking monoclonal antibody (mAb) ipilimumab and the…
- Trial name
- myDAvIpNi (NCT03707808)
- Testing
- intratumoral injection of autologous CD1c (BDCA-1)+ myDC, Intratumoral injection of ipilimumab and AS01b, IV nivolumab
- Where
- Belgium
- Volunteers
- 18 people
- Sponsor
- Universitair Ziekenhuis Brussel
Lymphoma
SWOG-9245 Collecting and Storing Tissue Samples From Patients With Relapsed or Recurrent Non-Hodgkin Lymphoma After Treatment on a Southwest Oncology Group Clinical Trial
RATIONALE: Collecting and storing samples of tissue from patients with non-Hodgkin lymphoma to study in the laboratory may help the study of cancer in the future.
- Trial name
- NCT00898872
- Testing
- cryopreservation
- Where
- 82 sites in United States
- Volunteers
- 32 people
- Sponsor
- SWOG Cancer Research Network
Neoplasms
Phase II Study With Hiltonol and Dendritic Cells in Solid Tumors
In this phase II study, patients with solid tumors will receive treatment with hiltonol and autologous dendritic cells.
- Trial name
- NCT01734564
- Testing
- Hiltonol and autologous dendritic cells, Hiltonol, dendritic cells and radiation
- Where
- Spain
- Volunteers
- 15 people
- Sponsor
- Clinica Universidad de Navarra, Universidad de Navarra
HIV-1 Infection, HIV Infections
A Pilot Study of a Dendritic Cell Vaccine in HIV-1 Infected Subjects
The purpose of the study is to find out whether an experimental autologous dendritic cell vaccine is safe, well tolerated, and whether it can strengthen the immune system's response to HIV.
- Trial name
- PARC002 (NCT00833781)
- Testing
- mRNA-transfected autologous dendritic cells, autologous dendritic cells with no mRNA transfection
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Massachusetts General Hospital
Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) International Registry
Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) is a very rare hematologic malignancy. Despite recent advances, at present there is no consensus on the optimal treatment of BPDCN.
- Trial name
- NCT05430971
- Where
- 22 sites in United States, Armenia and 13 more
- Volunteers
- 200 people
- Sponsor
- Immune Oncology Research Institute
Melanoma, Neoplasm Metastasis
Vaccination of Patients With Stage IV Melanoma With Dendritic Cells
The purpose of this study is to test a novel dendritic cell (DC) vaccine in patients with Stage IV melanoma.
- Trial name
- NCT00125749
- Testing
- Dendritic cell vaccination
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Baylor Research Institute
Breast Cancer
Dendritic Cell Based Therapy for Breast Cancer Patients
The primary aim of this study is to investigate time to progression in breast cancer patients vaccinated with autologous dendritic cells pulsed with peptides in combination with adjuvant aromatase inhibitor (AI), Thymosin 1 alpha…
- Trial name
- NCT00935558
- Testing
- DC vaccine, aromatase inhibitor
- Where
- Denmark
- Sponsor
- Inge Marie Svane
Lymphoma, Non-Hodgkin, Diffuse Large B-cell Lymphoma
Phase II Study to Evaluate the Combination of Rituximab and DepoCyte® in the C5R Chemotherapy Protocol in Patients Between the Ages of 18 and 60 Years With Primary Cerebral Non-Hodgkin Lymphoma and Systemic Diffuse Large B-cell Lymphoma With Neuromeningeal Invasion at Diagnosis
The purpose of this study is to measure the rate of complete response (CR and UCR) at the end of a course of immuno-chemotherapy: before cerebral radiotherapy for PCL after the course of immuno-chemotherapy for aggressive…
- Trial name
- NCT00553943
- Testing
- Rituximab, Cytarabine
- Where
- 46 sites in Belgium, France
- Volunteers
- 60 people
- Sponsor
- Lymphoma Study Association
Rheumatoid Arthritis
Tolerogenic Dendritic Cell Therapy for Rheumatoid Arthritis
Rationale: In rheumatoid arthritis, immune cells cause joint inflammation and destruction in response to autoantigens. Immunosuppressive therapies offer relief but fail to induce tolerance to autoantigens.
- Trial name
- TOLERANT (NCT05251870)
- Testing
- autologous mature tolerogenic monocyte-derived Dendritic Cells loaded with the B29 peptide of HSP70
- Where
- 3 sites in Netherlands
- Volunteers
- 18 people
- Sponsor
- UMC Utrecht